These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 17912445

  • 1. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
    Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS.
    Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
    [Abstract] [Full Text] [Related]

  • 2. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
    Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O.
    Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
    [Abstract] [Full Text] [Related]

  • 3. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [Abstract] [Full Text] [Related]

  • 4. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
    Siders WM, Halloran PJ, Fenton RG.
    Cancer Res; 1996 Dec 15; 56(24):5638-46. PubMed ID: 8971169
    [Abstract] [Full Text] [Related]

  • 5. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
    Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS.
    Stem Cells; 2008 Mar 15; 26(3):831-41. PubMed ID: 18192232
    [Abstract] [Full Text] [Related]

  • 6. Conditionally replicative adenoviral vectors for malignant glioma.
    Sonabend AM, Ulasov IV, Lesniak MS.
    Rev Med Virol; 2006 Mar 15; 16(2):99-115. PubMed ID: 16416455
    [Abstract] [Full Text] [Related]

  • 7. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
    Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E.
    J Gene Med; 2004 Nov 15; 6(11):1216-27. PubMed ID: 15459967
    [Abstract] [Full Text] [Related]

  • 8. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids.
    Grill J, Van Beusechem VW, Van Der Valk P, Dirven CM, Leonhart A, Pherai DS, Haisma HJ, Pinedo HM, Curiel DT, Gerritsen WR.
    Clin Cancer Res; 2001 Mar 15; 7(3):641-50. PubMed ID: 11297260
    [Abstract] [Full Text] [Related]

  • 9. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H.
    Gene Ther; 2004 Nov 15; 11(21):1551-8. PubMed ID: 15343358
    [Abstract] [Full Text] [Related]

  • 10. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.
    Hurtado Picó A, Wang X, Sipo I, Siemetzki U, Eberle J, Poller W, Fechner H.
    Mol Ther; 2005 Apr 15; 11(4):563-77. PubMed ID: 15771959
    [Abstract] [Full Text] [Related]

  • 11. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
    Siders WM, Halloran PJ, Fenton RG.
    Cancer Gene Ther; 1998 Apr 15; 5(5):281-91. PubMed ID: 9824047
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo targeting of gene expression to melanoma cells.
    Vile RG, Hart IR.
    Cancer Res; 1993 Mar 01; 53(5):962-7. PubMed ID: 8439971
    [Abstract] [Full Text] [Related]

  • 13. Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models.
    Mizuno M, Ryuke Y, Yoshida J.
    Cancer Gene Ther; 2002 Oct 01; 9(10):825-9. PubMed ID: 12224023
    [Abstract] [Full Text] [Related]

  • 14. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.
    Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, Yu JS.
    Cancer Gene Ther; 1997 Oct 01; 4(6):345-52. PubMed ID: 9408604
    [Abstract] [Full Text] [Related]

  • 15. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
    Nettelbeck DM, Rivera AA, Balagué C, Alemany R, Curiel DT.
    Cancer Res; 2002 Aug 15; 62(16):4663-70. PubMed ID: 12183423
    [Abstract] [Full Text] [Related]

  • 16. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
    Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, Lesniak MS.
    J Gene Med; 2007 Mar 15; 9(3):151-60. PubMed ID: 17351980
    [Abstract] [Full Text] [Related]

  • 17. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
    Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA, Gerritsen WR.
    Cancer Res; 2005 Oct 15; 65(20):9398-405. PubMed ID: 16230403
    [Abstract] [Full Text] [Related]

  • 18. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus.
    Ito H, Aoki H, Kühnel F, Kondo Y, Kubicka S, Wirth T, Iwado E, Iwamaru A, Fujiwara K, Hess KR, Lang FF, Sawaya R, Kondo S.
    J Natl Cancer Inst; 2006 May 03; 98(9):625-36. PubMed ID: 16670388
    [Abstract] [Full Text] [Related]

  • 19. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
    Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD.
    Gene Ther; 2006 Feb 03; 13(3):206-15. PubMed ID: 16307003
    [Abstract] [Full Text] [Related]

  • 20. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
    Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB.
    J Neurosurg; 2006 Apr 03; 104(4):583-92. PubMed ID: 16619663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.